ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly endocrinology — U.S. revenue ($M) [legacy] ($M)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q4 2019
2,348
Period ended Dec 31, 2019
Change on a year earlier
+11.9%
2,098 in Q4 2018
History
12 quarters
Since Q1 2017
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Endocrinology — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2019 | Dec 31, 2019 | 2,348 | +11.9% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,987 | +10.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,102 | +10.6% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,874 | +9.2% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,098 | +11.6% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,797 | +10.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,901 | +22.5% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,716 | +30.3% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,880 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,624 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,552 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,317 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Endocrinology — U.S. revenue ($M) [legacy] ($M), quarterly Q1 2017–Q4 2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_endocrinology_us_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.